Fondaparinux Market Growth Factors, Competitive Landscape and Revenue Forecast till 2024

Posted on 2021-02-10 by researchinsights in Healthcare // 0 Comments

Felton, Calif., USA, Feb. 10, 2021 — /EPR Network/ —

Global Fondaparinux Market is expected to reach USD 686.3 billion by 2024. Fondaparinux is also termed as Fondaparinux sodium or Natural heparin pentasaccharide is an anticoagulant medication chemically related to low molecular weight heparins. Its trade name is Arixtra. Its molecular formula is C31H53N3O49S8 and molecular weight is 1508.217 g/mol. Factor Xa inhibits its activity and interrupts the blood coagulation cascade by stopping thrombus development and thrombin formation. It is a synthetic glucopyranoside with antithrombotic activity. The Fondaparinux Market is estimated to grow at a significant CAGR of 7.8% over the forecast period as the scope and its applications are rising enormously across the globe.

Growing number of hip and knee surgeries, mounting cooperation between major players for securing the intellectual property rights (IPRs), growing aging population and diseases like orthopedic conditions and heart infections are documented as major factors of Fondaparinux Market that are estimated to enhance the growth in the years to come. However, severe side effects of drugs may restrain overall market in the coming years. Fondaparinux Market is segmented based on product type, application, end user, and region.

Access Fondaparinux Market Report with TOC @ https://www.millioninsights.com/industry-reports/fondaparinux-market

Generics drug and branded drug are the product types that could be explored in Fondaparinux during the forecast period. The market may be categorized based on applications like abdominal surgery, orthopedics (knee or hip replacement), cardiovascular, and others that could be explored in the forecast period. Home care settings, clinics, ambulatory surgical centers, hospitals, diagnostic centers, and other end users could be explored in Fondaparinux during the forecast period.

The key players of Fondaparinux industry are Kaifeng Pharmaceutical, Pfizer, Inc., WisMed Pharmaceuticals, Bayer Healthcare AG, Eisai Inc., GlaxoSmithKline Plc., Bristol-Myers Squibb Company, BoehringerIngelheim, Aspen Holdings, Sanofi S.A., Abbott India Limited, and Apotex. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.

Globally, North America accounted for the substantial market share of Fondaparinux and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be presence of key manufacturers in the region, growing awareness among populace regarding brand and upcoming drugs, and technological enhancements as growing aging population. The United States is a major consumer of Fondaparinux in this region.

Request a Sample Copy of Fondaparinux Market Report @ https://www.millioninsights.com/industry-reports/fondaparinux-market/request-sample

Table of Content

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Introduction

Chapter 4 Manufacture

Chapter 5 Cost Structure

Chapter 6 Worldwide Key Vendors

Chapter 7 Market Status

Chapter 8 Market Overview (Variables, Trends & Scope)

Chapter 9 Market Forecast

Chapter 10 Market Dynamics

Chapter 11 Investment Feasibility

Visit Our Blog: https://marketreportsassistance.wordpress.com

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Matched content

Editor’s pick